Kyverna Therapeutics, Inc.
Most recent annual filing: 2026-03-26
Pipeline (7 active programs)
miv-cel
mivocabtagene autoleucel · KYV-101 · KYSA-6miv-cel
mivocabtagene autoleucel · KYV-101KYV-102
- Undisclosed indication
KYV-201
- Undisclosed indication
Technology platforms
Ingenui-T · ElevateBio BaseCamp
Proprietary whole blood rapid manufacturing process for CAR T-cell therapies, designed to eliminate apheresis starting material and reduce manufacturing turnaround time; focus on autologous CD19 CAR T for autoimmune diseases
Targets: CD19
Biotech Distilled coverage (3)
- 2026-05-12 UPDATE: Kyverna Therapeutics (KYTX) - The BLA Clock Starts 🔒 Paid
- 2026-04-27 UPDATE: Kyverna Therapeutics (KYTX) - The SPS Receipts Land, And They’re Better Than the Topline 🔒 Paid
- 2026-04-22 Kyverna Therapeutics (KYTX) - Scientific Deep Dive for Miv-Cel and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.